VC firms
Oberland Capital provides innovative financing solutions to companies and royalty holders in the healthcare industry.
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 18
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 16, 2026 | TytoCare Secures $25M and Appoints Adam Pellegrini as CEO | Adam Pellegrini, CEO at TytoCare What You Should Know Telehealth innovator TytoCare has announced a $25 million-plus growth financing round alongside the high-profile appointment of digital health veteran Adam Pellegrini as Chief Executive ... |
| Apr 2, 2026 | ImmunityBio: $100 Million Financing To Support Global Expansion And Immunotherapy Pipeline | ImmunityBio announced $100 million in financing transactions, including $75 million in non-dilutive funding, aimed at strengthening its balance sheet and supporting global expansion and advancement of its broader immunotherapy pipeline. The... |
| Jan 30, 2026 | Primmune Therapeutics Raises $8.6M in Additional Series B Funding | Primmune Therapeutics, a Carlsbad, CA-based clinical-stage therapeutics company, raised $8.6M in additional Series B funding. Backers included Bioqube Ventures, Oberland Capital and Samsara Biocapital. The raise brought the total of Series ... |
| Jan 30, 2026 | Primmune Therapeutics: $8.6 Million Raised For Cclinical Development Of PRTX007 | Primmune Therapeutics announced it has completed an additional $8.6 million close of its Series B financing, bringing the total amount raised in the round to $23.3 million. The latest close included participation from Bioqube Ventures, Ober... |
| Jan 14, 2025 | Verastem Oncology: $150 Million Credit Facility Deal Signed | Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced a new credit facility for up to $150 million and an equity investment of $7.5 million with Ober... |
| Dec 16, 2021 | Zealand Pharma A/S Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital | Zealand Pharma A/S announced a financing agreement with Oberland Capital Management LLC ("Oberland Capital"). The agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note (the"... |
| May 5, 2020 | Oberland Capital nabs $1.05B raise for late-stage plays, handing out cash for royalties W h i t e p a p e r Weighing the Costs: | Come on in, the water’s warm. After billions already raised by VC firms since the advent of the pandemic for life science companies, Oberland Capital has tossed more than $1 billion into the pot. Sponsored by Agilent Technologies How would ... |
| May 5, 2020 | Oberland Capital Raises $1.05B Healthcare Royalty Fund | Oberland Capital Management LLC announced the closing of the Oberland Capital Healthcare Solutions Fund and affiliated funds, with $1.05 billion of capital commitments at the Fund's hard cap. The Solutions Fund will provide capital to bioph... |
| May 5, 2020 | Oberland Capital nabs $1.05B raise for late-stage plays, handing out cash for royalties | Come on in, the water’s warm. After billions already raised by VC firms since the advent of the pandemic for life science companies, Oberland Capital has tossed more than $1 billion into the pot. This will be added to an increasingly large ... |
Show more
Reviews 0
FAQ about Oberland Capital
How many startups has Oberland Capital invested in?
Oberland Capital has 1 portfolio company on Parsers VC.
What has the press written about Oberland Capital?
Parsers VC has collected 18 articles mentioning Oberland Capital, among them “TytoCare Secures $25M and Appoints Adam Pellegrini as CEO” (Jul 16, 2026) and “ImmunityBio: $100 Million Financing To Support Global Expansion And Immunotherapy Pipeline” (Apr 2, 2026).
Is Oberland Capital still active?
Yes, Oberland Capital is active; its latest activity on Parsers VC dates from Jul 16, 2026.